SRSF2 and systemic mastocytosis: Midostaurin treatment in systemic mastocytosis patients has shown that patients with one or more mutations in the S/A/R (SRSF2, ASXL, or RUNX1) panel have a lower survival rate and a higher progression rate to AML or mast cell leukemia than patients without mutations.